No Data
Jupiter Neurosciences, Inc. Initiates Patient Enrollment for Phase 2a RESET Trial of JOTROL in Parkinson's Disease
Express News | Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a Reset Trial in Parkinson’s Disease
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection With Its ~$2 Million Registered Direct Offering
Jupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson's Program and Strengthen Balance Sheet
Express News | Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
12 Health Care Stocks Moving In Thursday's After-Market Session
Uma Vaidhy : thanks mate @Cochise49
. loaded some !